Viking Therapeutics Inc (NASDAQ:VKTX) Sellers Decreased Their Shorts By 0.3%

June 27, 2018 - By Michael Day

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

Viking Therapeutics Inc (NASDAQ:VKTX) reported a decrease of 0.3% in shares shorted. In June was announced VKTX’s total 2.91M shares shorted by FINRA. The 2.92M previous shares are down with 0.3%. Viking Therapeutics Inc (NASDAQ:VKTX) has 892,100 shares average volume. It’ll cost 3 days for VKTX to restore its former position. Viking Therapeutics Inc float short is 15.78%.

VKTX is reaching $10.35 during the last trading session, after decreased 0.58%.Currently Viking Therapeutics, Inc. is uptrending after 320.16% change in last June 27, 2017. VKTX has also 1.30M shares volume. VKTX outperformed the S&P500 by 307.59%.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The company has $616.43 million market cap. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Currently it has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

In total 4 analysts cover Viking Therapeutics (NASDAQ:VKTX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:VKTX)’s analyst reports since March 8, 2018 according to StockzIntelligence Inc. The company rating was reinitiated by H.C. Wainwright on Monday, March 26. On Friday, June 1 the stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given by H.C. Wainwright. On Friday, June 1 Maxim Group maintained the shares of VKTX in report with “Buy” rating. On Thursday, March 8 the rating was maintained by Roth Capital with “Buy”.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news posted recently go to: Seekingalpha.com, Fool.com, Fool.com, Fool.com or Seekingalpha.com. The titles are as follows: “Viking Therapeutics: Sell The Pop On The Sympathy Play” posted on June 01, 2018, “Viking Therapeutics, Buy the Dip?” on June 26, 2018, “Why Viking Therapeutics Stock Is On Fire Today” with a publish date: May 31, 2018, “3 Growth Stocks at Deep-Value Prices” and the last “Viking Therapeutics: Hallmark Moment” with publication date: June 13, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: